Status:

COMPLETED

Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors

Lead Sponsor:

Oticon Medical

Conditions:

Sensorineural Hearing Loss

Cochlear Hearing Loss

Eligibility:

All Genders

Phase:

NA

Brief Summary

The present study aims to evaluate patient satisfaction and audiological performance with their current cochlear implant speech processor, the Neuro 1, and to compare it with the satisfaction and perf...

Detailed Description

Nowadays, cochlear implants (CI) are successfully used to rehabilitate severe to profound sensorineural hearing loss. Oticon Medical recently developed a new cochlear implant system, including a new i...

Eligibility Criteria

Inclusion

  • informed consent
  • Native French speaker or fluent French speaker
  • Patient already fitted with one or two speech processor Neuro 1 for at least 5 months

Exclusion

  • vulnerable patients, at the exception of children (pregnant women, persons under guardianship)
  • No Social security affiliation
  • non-compliant patient

Key Trial Info

Start Date :

October 2 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 11 2019

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT03288753

Start Date

October 2 2017

End Date

January 11 2019

Last Update

March 23 2023

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Hôpital Pellegrin

Bordeaux, France, 33000

2

Hôpital Roger Salengro

Lille, France, 59037

3

Hôpital Edouard Herriot

Lyon, France, 69003

4

CHRU de Nancy Hôpital central

Nancy, France, 54035